Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
LEQVIO (inclisiran) is a subcutaneous oligonucleotide therapeutic approved by the FDA on December 22, 2021, developed by Novartis. It is indicated for familial hypercholesterolemia, atherosclerotic cardiovascular disease, coronary artery disease, acute coronary syndrome, and related lipid disorders. Inclisiran works through an RNA interference mechanism to reduce LDL cholesterol levels. The product represents a novel mechanism in lipid management and is currently in its peak commercial lifecycle stage.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients
Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea)
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Worked on LEQVIO at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moLEQVIO creates opportunities for specialized roles including brand managers focused on specialty/rare disease marketing, field-based medical science liaisons trained in lipidology and cardiovascular disease, and reimbursement specialists navigating formulary access for high-cost oligonucleotide therapies. Critical skills include deep knowledge of familial hypercholesterolemia patient pathways, payer negotiations, and the ability to educate cardiologists and lipidologists on the mechanism and clinical benefits of RNA interference therapy. Currently, zero open roles are linked to this product in the database, reflecting its early commercial stage and niche market positioning.